As a result, specifically disrupting the ERG-BRD4 interaction with BET inhibitors may serve an equally important, yet disparate purpose to prevent PCa progression, in addition to disrupting the AR-BRD4 interaction and AR-mediated expression of TMPRSS2-ERG fusions. The gene discussed is BRD4; the disease is posterior cortical atrophy.